{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-23-000049","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.309669+00:00","generated_at":"2026-06-15T11:06:31.629543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q1 revenue up 18% to $36.7M; net loss narrows; FDA clears Axoguard HA+","bullets":["Net revenue $36.7M (+18% YoY); net loss $7.1M vs $11.5M prior year.","Adjusted net loss $4.1M ($0.10/share) vs $8.5M ($0.20/share) prior year.","FDA 510(k) clearance for Axoguard HA+ Nerve Protector; pilot launch Q2, full launch Q3.","Full-year 2023 revenue guidance reaffirmed at $154M-$159M.","Cash and investments $44.1M at March 31, down from $55.0M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-23-000049","json":"https://secwatch.observer/filing/0000805928-23-000049.json","markdown":"https://secwatch.observer/filing/0000805928-23-000049.md","text":"https://secwatch.observer/filing/0000805928-23-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000049/0000805928-23-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000049/axgn-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:06:31.629543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"400c97efc1f5bfec865bb6a294e6226eab97c2b3","claim":"Axogen, Inc. reported first quarter ended March 31, 2023 results: revenue $36.7 million, net income $7.1 million, EPS $0.17 per share. Guidance reaffirmed.","evidence_excerpt":"today reported financial results and business highlights for the first quarter ended March 31, 2023. First Quarter Financial Results and Business Highlights • Net revenue was $36.7 million, an increase of 18% over the first quarter of 2022. • Gross margin was 81.7%, compared to 82.1% in the first quarter of 2022. • Net loss of $7.1 million, or $0.17 per share,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/805928/000080592823000049/0000805928-23-000049-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$36.7 million"},{"label":"Net income","value":"$7.1 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}